ArticleHealth services research2002
Quantifying components of drug expenditure inflation: the British Columbia seniors' drug benefit plan.
Article in Health services research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The impacts of the national volume-based procurement policy on the chronic disease medication market in China's public hospitals: a case study of medications for diabetes.BMC health services research · 2025Article
- Assessment of Financial Impact of Expanding the Scope of Drug Usage in South Korea.International journal of health policy and management · 2025Article
- Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation.PloS one · 2024Article
- Main drivers of diabetes pharmaceuticals expenditures: evidence from OECD countries and Iran.Journal of diabetes and metabolic disorders · 2023Article
- Drivers of federal spending in pharmaceuticals of the Specialized Component: measurement and analysis.Revista de saude publica · 2021Article
- Decomposition Analysis of Spending and Price Trends for Biologic Antirheumatic Drugs in Medicare and Medicaid.Arthritis & rheumatology (Hoboken, N.J.) · 2020Article
- Trends in the costs of drugs launched in the UK between 1981 and 2015: an analysis of the launch price of drugs in five disease areas.BMJ open · 2019Article
- Trends in medicines procurement by the Brazilian federal government from 2006 to 2013.PloS one · 2017Article
- Factors Contributing to Increases in Prescription Drug Expenditures Borne by National Health Insurance in South Korea.Yonsei medical journal · 2016Article
- [Assurance-médicaments nationale: Le moment d'aller de l'avant].Canadian family physician Medecin de famille canadien · 2016Article
- National pharmacare: Time to move forward.Canadian family physician Medecin de famille canadien · 2016Article
- Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004.BMC health services research · 2010Article
- Reference drug programs: effectiveness and policy implications.Health policy (Amsterdam, Netherlands) · 2007Article
- Prescription drug expenditures and population demographics.Health services research · 2006Article
- Drug expenditure trends in the Canadian provinces: magnitude and causes from 1998 to 2004.Healthcare policy = Politiques de sante · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo quantify the relative and absolute importance of different factors contributing to increases in per capita prescription drug costs for a population of Canadian seniors. DATA SOURCES/STUDY
settingData consist of every prescription claim from 1985 to 1999 for the British Columbia Pharmacare Plan A, a tax-financed public drug plan covering all community-dwelling British Columbians aged 65 and older. STUDY
designChanges in per capita prescription drug expenditures are attributed to changes to four components of expenditure inflation: (1) the pattern of exposure to drugs across therapeutic categories; (2) the mix of drugs used within therapeutic categories; (3) the rate of generic drug product selection; and (4) the prices of unchanged products. DATA COLLECTION/EXTRACTION
methodsData were extracted from administrative claims files housed at the UBC Centre for Health Services and Policy Research. PRINCIPAL
findingsChanges in drug prices, the pattern of exposure to drugs across therapeutic categories, and the mix of drugs used within therapeutic categories all caused spending per capita to increase. Incentives for generic substitution and therapeutic reference pricing policies temporarily slowed the cost-increasing influence of changes in product selection by encouraging the use of generic drug products and/or cost-effective brand-name products within therapeutic categories.
conclusionsThe results suggest that drug plans (and patients) would benefit from more concerted efforts to evaluate the relative cost-effectiveness of competing products within therapeutic categories of drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.